logo

VRAX

Virax Biolabs Group·NASDAQ
--
--(--)
--
--(--)
1.06 / 10
Underperform

Fundamental assessment is challenging (1.1/10). Key concerns include sub-par Asset-MV (-0.5007) and Revenue-MV (-0.2574) rankings, while Net profit / Total profit (%) at 97.8% offers limited relief. Historical back-tests for most factors show negative monthly returns, reinforcing defensive positioning.

Fundamental(1.06)SentimentTechnical

Analysis Checks(4/10)

Revenue-MV
Value-0.26
Score0/3
Weight12.73%
1M Return-3.84%
ROA (%)
Value-101.88
Score0/3
Weight17.36%
1M Return-7.78%
Net profit attributable to parent company shareholders / Net profit (%)
Value99.90
Score2/3
Weight5.83%
1M Return-1.71%
Net income-Revenue
Value-0.17
Score1/3
Weight8.23%
1M Return-2.55%
Cash-UP
Value-0.06
Score2/3
Weight14.22%
1M Return-4.86%
Annualized net profit margin on total assets (%)
Value-101.88
Score0/3
Weight17.36%
1M Return-7.78%
Interest coverage ratio (EBIT / Interest expense) (%)
Value42.48
Score2/3
Weight6.57%
1M Return-1.95%
Asset-MV
Value-0.50
Score2/3
Weight-6.84%
1M Return1.60%
Cash-MV
Value-0.07
Score1/3
Weight15.62%
1M Return-5.64%
Net profit / Total profit (%)
Value97.80
Score1/3
Weight8.92%
1M Return-2.89%
Is VRAX fundamentally strong?
  • VRAX scores 1.06/10 on fundamentals and holds a Premium valuation at present. Backed by its -44.40% ROE, -189348.33% net margin, -0.30 P/E ratio, 0.33 P/B ratio, and 53.26% earnings growth, these metrics solidify its Underperform investment rating.